Primo Capital Launches Primo Biotech Lazio VC Fund

TL;DR

Milan-based Primo Capital has launched Primo Biotech Lazio, a new early-stage venture fund aimed at converting Rome's university and clinical-research ecosystem into fundable biotech companies. Trade press pegs the fund at roughly €40 million, anchored by regional development agency Lazio Innova and healthcare pension fund Fondazione ENPAM as limited partners, though notably, Primo Capital's own announcement doesn't disclose a fund size at all. It's the latest expansion of a platform that's grown from a single VC shop into a €537 million, four-vertical alternative-investments manager in under two years.

Key Takeaways

Regional development capital is becoming a real LP category. Lazio Innova's commitment comes through its "LAZIO Venture 2" programme, an EU-co-financed fund-of-funds mechanism designed to seed VC vehicles tied to local research clusters. Primo Biotech Lazio was reportedly one of six funds selected under that programme. If it works, it's a template other Italian and EU regions with strong university and clinical-research infrastructure but thin private VC coverage could realistically copy.

The strategy is concentrated-lead, not spray-and-pray. Primo Capital describes itself as acting primarily as a lead investor supporting portfolio companies across the full lifecycle, from scientific validation through clinical and regulatory strategy to eventual licensing, M&A, or exit. That's a meaningfully more hands-on posture than a typical seed fund writing dozens of small checks, and it implies a small, carefully selected portfolio rather than broad market coverage.

This is a platform extension, not a standalone bet. Primo Capital rebranded from Primo Ventures in November 2024 and has since built out four verticals, Digital, Space, Health, and Climate, across seven funds and roughly €537 million in committed capital. Primo Biotech Lazio slots alongside the firm's existing Primo Health private-equity fund, though no public source clarifies whether it's a standalone vehicle or a compartment of that existing fund, worth watching for clarification as the fund starts deploying.

The fund's own silence on size is itself notable. Every euro figure attached to this story, the reported €40 million total and Lazio Innova's reported €17.5 million commitment, comes from trade press (principally BeBeez), not from Primo Capital's own materials. Funds increasingly go quiet on size for competitive or political reasons, but when a public pension fund and a regional development agency are co-investing, that opacity is worth flagging rather than waving through.

Fund Overview

Fund Name: Primo Biotech Lazio
Fund Size: Reportedly approximately €40 million (~$43 million), per trade press; not confirmed in Primo Capital's own announcement
Stage: Early-stage biotech and life-sciences spinouts
Check Size: Not disclosed
Geography: Lazio region, Italy, with a permanent office planned in Rome
Focus: Biotechnology and innovative technologies applied to the life sciences, sourced from the region's universities, IRCCS clinical-research institutes, and pharma production hubs
Key LPs: Lazio Innova (via the LAZIO Venture 2 programme, reportedly around €17.5 million), Fondazione ENPAM

Why This Fund Matters

Italy's biotech sector has long had the research inputs, strong universities, a dense network of IRCCS clinical-research institutes, and a pharmaceutical manufacturing base, without a commensurate depth of early-stage capital willing to bridge academic discovery into funded companies. Rome and the broader Lazio region specifically sit on a meaningful cluster of that research infrastructure, and a dedicated fund built to mine it is a rational, if overdue, bet.

The Lazio Innova structure is worth understanding on its own terms. Regional development agencies across the EU have experimented with fund-of-funds vehicles for years, but Italy's PR FESR-financed LAZIO Venture 2 programme, which reportedly evaluated and scored multiple fund managers before selecting Primo among six, is a more competitive and structured process than the typical government LP check. That selection discipline should give other LPs some comfort that this wasn't simply a political allocation.

Fondazione ENPAM's presence as a repeat Primo Capital LP (it's also a cornerstone investor in the firm's existing Primo Health fund) signals a pension fund that's comfortable making a second commitment to the same manager's healthcare-adjacent strategy. For a category, biotech venture, that requires patient, long-duration capital, a pension fund's participation is a more natural fit than most LP types, and repeat commitments are a stronger signal than first-time ones.

Primo Capital's broader platform build is the context that makes this fund more than a one-off. Going from a single-strategy VC firm to a €537 million, four-vertical alternative-investments manager in under two years is an aggressive expansion, and Primo Biotech Lazio reads as part of a pattern: identify a regional or sector-specific capital gap, pair it with a public or institutional cornerstone LP, and stand up a dedicated vehicle. Whether that platform-building pace outruns the firm's execution capacity is the open question.

The Team

Letizia Goretti and Michele Cerqua are the General Partners leading Primo Biotech Lazio specifically, both part of Primo Capital's broader Health vertical. Professor Sergio Abrignani serves as Scientific Adviser to the fund; his specific institutional affiliation wasn't disclosed in available materials. It's worth noting Primo Capital's Health vertical also includes other General Partners, Andrea Pavero, Carlo Vanoli, and Emiliano Tonelli, who lead the firm's existing Primo Health private-equity fund rather than this new biotech vehicle, a distinction worth keeping straight given how closely the two funds sit within the same vertical.

What This Means for Founders

Early-stage biotech founders emerging from Lazio's university and clinical-research ecosystem, or willing to establish a Rome presence, are the clear target here. Given Primo's stated lead-investor, full-lifecycle approach, founders should expect a genuinely hands-on relationship rather than a passive check, support that's meant to extend from scientific validation through regulatory strategy and eventually to licensing or exit conversations.

Because the fund's actual capital base hasn't been confirmed publicly, founders in diligence conversations would be reasonable to ask directly about check-size range and reserve capacity for follow-on rounds, information that isn't available in any public source as of this writing.

Fund Momentum Take

We'd flag two things for anyone tracking this fund going forward. First, the undisclosed fund size is a genuine gap, not just a stylistic choice, when public pension money and regional development capital are involved, more transparency is generally warranted, and its absence here is worth watching for whether it gets clarified as the fund starts deploying. Second, if the reported €40 million figure holds, that's a modest pool for a strategy built around leading rounds in a capital-intensive category like biotech; the fund's actual staying power through follow-on rounds will be the real test of whether the lead-investor positioning is sustainable or aspirational.

On the upside, the combination of a competitively selected regional LP, a repeat pension-fund investor, and a management team building out a genuinely differentiated regional thesis is a more credible setup than most one-off government-backed funds manage. Our bet: this is a fund worth revisiting once its first few portfolio companies are public, both to see whether the lead-investor model holds at this fund size, and to see whether Lazio's research ecosystem produces the volume of fundable biotech companies the thesis assumes.

Frequently Asked Questions

How big is the Primo Biotech Lazio fund?
Trade press reports the fund at approximately €40 million, though Primo Capital's own announcement does not disclose a specific fund size.

Who are Primo Biotech Lazio's key LPs?
Lazio Innova, via its LAZIO Venture 2 programme, reportedly committing around €17.5 million, and Fondazione ENPAM, Italy's healthcare-sector pension fund.

What does Primo Biotech Lazio invest in?
Early-stage biotechnology and life-sciences companies, particularly spinouts from universities, clinical-research institutes, and the pharmaceutical ecosystem in Italy's Lazio region.

Who leads Primo Biotech Lazio?
General Partners Letizia Goretti and Michele Cerqua lead the fund, with Professor Sergio Abrignani serving as Scientific Adviser.

How does Primo Biotech Lazio fit into Primo Capital's broader platform?
Primo Capital operates four verticals, Digital, Space, Health, and Climate, across roughly €537 million in committed capital and seven funds. Primo Biotech Lazio sits within the Health vertical alongside the firm's existing Primo Health private-equity fund, though it's led by a distinct pair of General Partners.

---

Have a fund closing to announce? Submit your fund here.

Need help raising capital? Check out our Fundraising Advisory services.